Trials / Sponsors / ContraFect
ContraFect
Industry · 4 registered clinical trials.
| Status | Trial | Phase | Started |
|---|---|---|---|
| Terminated | Direct Lysis of Staph Aureus Resistant Pathogen Trial of Exebacase Staphylococcus Aureus Bacteremia, Staphylococcus Aureus Endocarditis | Phase 3 | 2019-12-20 |
| Completed | Safety, Efficacy and Pharmacokinetics of CF-301 vs. Placebo in Addition to Antibacterial Therapy for Treatment Staphylococcus Aureus Bacteremia, Staphylococcus Aureus Endocarditis | Phase 2 | 2017-05-23 |
| Completed | A Placebo-Controlled, Dose-Escalating Study to Examine the Safety and Tolerability of Single Intravenous Doses Staphylococcus Aureus Bloodstream Infections (BSI; Bacteremia) | Phase 1 | 2015-05-01 |
| No Longer Available | Expanded Access Study of Exebacase in COVID-19 Patients With Persistent MRSA Bacteremia MRSA Bloodstream Infection, MRSA Bacteremia, MRSA Right-sided Endocarditis | — | — |